Revance Therapeutics (NASDAQ:RVNC – Get Free Report) and Flora Growth (NASDAQ:FLGC – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends. Risk & Volatility Revance Therapeutics has a […]
StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a research report report published on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Other research analysts have also recently issued research reports about the company. Morgan Stanley reduced their price target on Revance Therapeutics from $26.00 […]
StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a report published on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock. Several other brokerages also recently issued reports on RVNC. Morgan Stanley reduced their price target on shares of Revance Therapeutics from $26.00 to $25.00 and set […]
Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $17.89 and last traded at $17.89, with a volume of 614736 shares changing hands. The stock had previously closed at $18.75. Wall Street Analysts Forecast Growth RVNC has been the […]
Revance Therapeutics, Inc. (RVNC) announced Monday that the U.S. Food and Drug Administration (FDA) has approved the first therapeutic indication for DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults.